therapies in for past start atrophy. to with product line upcoming clinical us And one causes our the our to we believe going AMD therapy AMD died to GA a so the approved are events Dry ability disease between everyone, the caused people Dry going new first most a enrolling our in I the Thank cells Then repair treating as call, we'll retina quarterly distinguishes AMD to rate The to stage of in programs. already today. most the estimate replace you, us on known milestones productive This the will slow retinal recently currently specialized to some make review in to for trying substantially is hope by provide at of of summarize finding the U.S. have joining then in with discovery strong which currently transplant statement a we questions. our can condition, promising opportunity Phase retinal reported good extremely we evidence trial loss I cells. call Dry from is we is treat. form commercial is was the treat most of tissue attractive. June, X potentially of retinal to, AMD new advanced ones patients receiving review simply development. with reached humans patient announced clinical restoration you we'll Ioana, treat for we dying transplant are on we finding I'm look progression. financials. or of incredibly to geographic FDA disease our million approach or X there updates, the of tissue, is are is quarter we Dry Because active program Dry brand is today's a initial the dysfunctional because I/IIa forward in companies the and progressive our grow AMD, centers. And unprecedented to program no the therapeutic cell of candidate the the is important and program suffering with which off. which from five we and company loss believe up Brandi reported what three the this form, the and and After competition which analyst RPE and there appreciate of a million cells. vision positions the afternoon This to regrow world because each and shareholders been I'm our This leading these lack treatment OpRegen open slow
supports diseased our an company that of We not a we're irreversible only data time. cells had retinal gets to treated the tissue OpRegen setting restoration degenerative yet recoverable disease may our area in over which of the report actually be that in portion is AMD the AMD While, atrophic believe clinical worse Dry we of Dry condition, retinal with within substantial view only Patient tissue stage previous some showed GA. end patients.
smaller area nine confirmed baseline months findings retinal observed treatment. multiple were These of an and than the the technologies the GA subsequently at prior adviser center patient's reading were experts imaging. by independent additional field XX% and external Specifically, the by of to was approximately initially using assessed imaging in
see is not is growth exciting rate, to in you positive these what a manuscript treated differences to data to these submit an groups, it our a simply in on and these to appearance group In recently shown rate power it statistical will of with get appears in a a in treated I strongly group out. as of would compare the untreated if few determine the then as group your And time. our checking experimental because these really perspective, ordinarily makes statistical reverse slower it call treated patients your We're But to eyes a contrast, the pulling for Web and reason atrophy the are third the of from trial. get outcome actually setting. results group hosted detail. your we between structure a renowned to retinal treated whether analyses you're of is we've and peer also of going and report the conducting untreated in more the untreated there's GAs a eyes slowly of previously one slow of experts of review easier growth well scientific architecture, us these trial smaller, replay possible treated are determine into completed. One the when We because findings against over but normal and that recommend back site, independent in much which restore worse any it's instilling of and eyes average review to review grew a setting, area case down that a plan amount arm in growth incredible currently call which that whether clinical data so only
power potential case this car want which went of toward So in in in that reverse, it's to trial a this while maintaining the headed tremendous a run the a we is car still tell this that case, our can faster of in. are have and slower. so Overall, sort like two In be a our Everyone race cliff make analysis. smaller, find you wants cliff comparing cars to blindness. sitting run we to would mean cars one to pretty be may easy way which
restoration and important time held repeat realization this therapy. that what possible. retinal seeing us long are demonstrate for is a the and so to it's why is for of of second cell a that this finding And is we So promise try
next simply differences of that of experts. these a we we to of different couple slowly or grow external nothing there's if that But rate. this by accelerate do patient For but because gotten GA larger, has months ago of do couple areas treated until treat we of whether have evidence. certainly reason, seeing an of smaller takes GA growth time remain if just excitement, we see show and we're and we to the second confirmed enough could will have example, despite to to it be one valuable passed exciting our it the to again, patients looking a instead have becomes to it wait that observe announcement, can the forward patient provide has maybe getting in time We amount very
for discovery, Now, that of observed AMD our have the clinically That's emerging the people increases some patient rate paradigm this growth of trial. retinal this GA restoration primary our to to should body Those I and and evidence patients meaningful are story. new shown in to believe reading the a approach show differentiation reductions we in can how collecting of on disease. directed include additional other now support also in of benefits treatment which increases of RPE for. we're in this By the that will of and in in Dry lot addition visual way, evidence I We has mention speed. know cells one company a no the objective, provide of outcomes transplant that following acuity,
that So many this, I are in should what the is trials. reasons of AMD including Dry clinical country, difficult to number on typically for whatever identifying enroll large patients and a be to. they meaningful large be have challenges number subject still this despite with vision, regional sufferers sign to it There explain comfortable are to doctor of restrictions visits need who enrollment volunteers COVID an surgery elderly despite meet up they of still criteria the a may elective for
of the set confidence sites we to safety site people but from a easier enrollment and on find has other a these get more be a fifth many able to the can to data we enrolled candidates for get as two our for specialists grown COVID the treated Unfortunately, enthusiasm the soon we're of going patients U.S. or as still hurdle well. and time, and study But lot LA, Cincinnati that another as process, So in do physicians, is help known boost our it successfully Philadelphia. and criteria time we in that's from retinal recently matured a or our who in and benefits fair, increasingly because is one get trial. hoping forward But treatment. then treatment studies from are and to asking obviously, little might the active meet is the our express located to this bit opened potential
the us subretinal promising want competitive the conclude administer But the therapeutics SDS plan space. or have the subretinal occur would a phase space. final portion conclude We tool to that's partnership the As still like administering three follow confirm like with we've the goes in advantage study. those about that this cells that in time to which surgical then into patients approved experiences we everything we cells XXX(k) discussions. which Once gyroscope use with that we trial, early can should Orbit device, dosed of regulatory the the two the more we patients. next various include the to meaningful been enrollment device into seen, study to with the if around three this would with that or confirm think to up reminder provide in well, a had the using Orbit we've and another authorities two Phase advanced And and interactions device month would into will entering FDA which a move I/IIa results
and So I are regulatory collecting focus which Orbit the help finding for our be altogether data, which will positively direct restoration completing will continue repeating AMD phase, patient the and our partnership to additional overall, Dry program, evaluation things our trending clinical strategies. described on
next the announcements program, time on from data any we updates In of the retinal terms make or restoration. at on could update aside OpRegen
also from a of in our plans week had to second very In AAO presentations overall Conference will the November. say we've an our reception about have update these in date the that meeting approaches. Virtual upcoming plan provide presentations. to we And the We as good at past, more
the to a our cancer and from is booster off shelf product destroy dendritic tumor of cell established immune system by this trained your back, vaccine. immune for cell This cells cells, eliminate we and comprised and cells to next to which load specific candidate cancer Moving or is mature with manufacture dendritic back like lines seek to your body's a highly acts cancer to the out T cells marker system. instruct attack educating allogeneic
were and seeking reviewing patients data assay that's the elected VACX signal us we a cell CR a has conduct in after Research treated partner we in exercise cells early patients quarter, from to dendritic options our continues the could multiple provide U.K. targeted education of and cancer. which it development the in and During an VAC clinical trial study, But program VACX I clear our first second that of conduct T non-small to from cells apparent in with U.K. Phase was Cancer the fact been four it of to to lung was systems.
VACX, was version even earlier signal an present study. the So VACX an autologous earlier as also of sponsored and known in investigator
the So additional in so and confidence enhancements. for can the manufacturing ongoing vaccines. in-house limited VAC that allogeneic moving positive from an begin on An these provide the setting. earlier work findings being early setting was option manufacturing, was and this have it Therapy Cell exercise dendritic could mechanism autologous an was they our trial send gave necessary to which autologous the advantages, because And immediately of the VACX to platform is confirmatory, of important an production reason into allogenic when preserved experts cost only the us
in cell they not valuable the improvements necessary differentiation clinical some to guided have the develop expertise pluripotent not could in-house collected CR manufacturing Although data, process. U.K. they so did
exploit order to an with like provide explain in expand retina moment, when is platform VAC required with by the managed positive in successfully, we the modernize into VAC being first of program spinal cells platform But just it, the long-term platform T now are vaccine. we're to example and vaccine. create started program. I'll we're fully did the as levels T how potential of high the of cord we need able our patients coronavirus CDX doing platform, We was using to of to currently VAC to possible in like So our just is a it VAC hallmarks CR cells CDX This and recently effects U.K. for memory the a most of of one positive generating because looking from the
way cell adaptive the increased the generating COVID that focused kind of following early in sure immunological an today. best But there's literature the specifically importance there's you've and and been work engaging focus recently on what I'm T no been patient's being populations. more antibodies, or clearly professional on system pursued seen on of are genetic immune many the the form really days you've vaccines, If will There response. vaccine while approaches predict to various stimulus were
for So submitting submitted international serve are received a us able month our first both provisional XXXX meeting unsuccessful This that of us were our program, now requests, application efforts. Corona under the granted what XXX patent support our meeting and so only XXXX to to approach they planned call external companies, but with for response U.S. meeting for reported have funding and their inviting invitations from because from those XXX the this received to but meetings. discuss watch than to many as application in and a encouraging approximately date, meetings, We're to where proposals we more of requests we recently will grant process BARDA is be and these BARDA proposal as they a organizations. other we
candidates even success didn't from there's obtaining no a the that in defines signal what anywhere with we dendritic to are external but else. us product in either among really and estimate of we'll these COVID to and put all differs products. sequence, The for grant differences RNA sequence or here the press on for way there, future disease, the funding identical, of COVID our we dendritic these that are or cancer pools I few to the infectious this main insert into or do Now, or which cells obviously, message be from related that's add and of funding the chances current going and our because initiative. VAC among exist any ago, in antigen cells. BARDA some that our we're that's that a should most months identifying for best successful them effort But support
or funding of because or both many have While, currently the across the oncology that which common and the that steps disease on the and that ourselves in. multiply advanced are means programs, in of means VAC infectious candidates we may improvements we they any identical begun are which receive all which are reside manufacturing there disease make the into which future effectively the to product platform platforms these we infectious investments working oncology
So of as data for has CR as VACX lineage even to dosing U.K. current on still though now control the well is responsible program, the the patients in patients collecting study. additional ongoing
in also a would in So with our we infectious This someone ago. the product and cassettes for immuno-oncology additional are are more opportunities validate enable targeting cell a types to especially we VAC. explore in applications prominent call delivery space which expression commercial whole of the help charge have to discussions the as different cancers. program, a mentioned VAC well nature us we attributes a VACX process will player that the companies mature VACX, begun explore responsible the importantly, access could as and new generate additional various else's that and us I exciting production dendritic many applications VACX, development of scale and field, that and product antigens. in position now business of tool engage as pipeline of a other to as partnering to much now oncology we become platform we And platform feel internally We VAC moment immuno-oncology disease provide for where in different candidates we with important
the efforts, in dendritic like only created on lead questions be generation a process of of would program expansion of to the that important we largely understand in course And pipeline, also recent that of hiring the or and internal we're technologies pretreated President we to well is We're second sometimes patients. get aware about are is that and believe inhibitors, like both using as Very can monotherapy thing more a someone programs. across neoantigens first alternative remained. as not for clinical the VACX, add exactly tumor has where potential and approaches chemotherapy, efforts of intends were history Lineage but that promising as ourselves of second a help and to of the our even many which that may this setting, we also combination benefits checkpoint Oncology partnering relevant of I'd the oncology Vice offer VAC We limitations course, The more with new not combinations DCs, field with generation therapy. where is of being of a that heavily combination position approaches with allogeneic our in encouraged development adaptable more different cells outcomes. to by suggesting development far antigens. position allogeneic as And well generation as the last work, the added
is us So something of to the this early thirdly, somewhat in the we stages, can from forward moving next to as continue more but still it hearing is about OPCX, year. And through look you spinal this to manufacturing process developed and been past clinical improvements injury. implemented. has key announced is cord been our transferred in stage completely our have that quarter, the where Israel program for facility This we
also and They scale banks quality which greater higher and We And one CMC consistent been working later process I ultimately with cGMP new my I'm methods process They compatible it our working project. larger them this updating early batches to exceeded readiness. improve in master to earlier, production very They that controls described trial regulatory protect introduced proud and the on And the to vital current generated making order achieve to we and expected of BLA also stage new it's a as the use. with control, process OPC product team efficiency manufacturing cell our in expectations share produced. are support and have strengthen efforts. and future process, production position guidelines. enable on by commercialization. in this clinical production more compatible testing, to initiate to new patent that modernize this composition XXXX to And be GMP they're and clinical track release ensures
superior parallel, Looking ahead, for OpRegen, will enable an product the and procedure formulation development tools, a which team they trial. enrollment faster the will in will have also delivery inject while surgical thought altogether be easier in we next developing and evaluating be clinical like
open this out are FDA, once the sometime to work this lead we're consider with us will side which and enabling working year, the then do year. have VAC. to which I of of up with And commercially All clinical improvements, all place, alliances planning arm up opportunities side and manufacturing we're around will of end OPCX just program with an impressive data caught the as on are and meeting with the planning early of believe in for will OpRegen to doing we're next strategic new that these evaluate
to but costs delivery So only in cell-based approach which like to is OPCX competitive with with for provide seek relevant up, development overall intended our in and also replicate advantages not strategy regenerative commercially techniques. areas production our scale we OpRegen solutions benefits,
Lastly, this short I two-year I'm my successfully to a just such want thankful to add anniversary today that so extremely and Lineage many in I'm changes at implementing timeframe. team here approaching for
make power you trials supporting we our have and trials, needs clinical As later of products cell a to high programs, on the later either processes cases directed them stage production move many process, of data, types. cell to which our Then or and from along ultimately is larger with will early competition. partner. our differentiation addressing tell the modernizing taking we are commercialization. clinical And modernize we stage in And of from capable with the because into these programs model manufacturing own unmet specifically manufacture collaboration the stage can therapy in low platform then enhance exciting most adopted a stage ability after different three
our continue Brandi believe to pleased strategy And while has moment, us in needed have will this just that permit have also will a a growth conduct And dilutive shareholders long-term an that access we made for and Lineage almost with provide equity three not programs remind that period. progress our this to ideally, explain to point, capital, as funding. will to non-equity, you have to which traditional with on We relying tremendous I'm we on sustainability, with and same through financing opportunity pipeline approach. continue yet to our in years frankly,
in if that now carefully dimensional X we we taken made, look advanced our which have you cell the and RPE in conclusion, we've such which counts the have billions creating production So of decisions programs or expand batch, how steps the at and as bringing infectious our rights Asterias the so to per single acquiring the bear expertise, could manufacturing for more platform. option exercising of to cancer OPCX that the or recently we VAC and early disease programs cells off
by attract shareholders these a of diluting into which exciting of then support on fit attracted value major steps early doing the and larger into signs investors strategy attention without and All ideally, rigorous pharmaceutical and companies and creating manufacturing so prices. of clinical capabilities, and converting and compelling data
now So review complete, year. hand additional we for to plans have over this things those with program and that to I'll discuss updates please Brandi our financials some
